应用CIK细胞治疗子宫内膜癌患者外周血T淋巴细胞亚群和NK细胞变化的临床观察

目的:观察应用细胞因子诱导杀伤细胞(cytokine-induced killer cells,CIK)联合化疗、内分泌治疗等治疗子宫内膜癌的临床疗效。方法:子宫内膜癌患者35例给予联合应用CIK细胞生物治疗6个疗程,其中11例患者TP(紫杉醇+顺铂)化疗联合CIK细胞生物治疗,15例患者醋酸甲地孕酮内分泌治疗联合CIK细胞生物治疗,9例患者单纯应用CIK细胞生物治疗。通过流式细胞术检测治疗前后患者T淋巴细胞亚群CD3+、CD4+、CD4+/CD8+比值以及NK细胞比例、KPS评分等指标变化,用统计学方法进行分析。结果:35例子宫内膜癌患者经联合CIK细胞生物治疗后,CD3+T细胞无显著变化,CD4+辅助T细胞显著增加,CD4+/CD8+比值显著升高,部分患者CD3-/CD16+56+的NK细胞较治疗前升高但无统计学意义,患者平均KPS评分提高10分(P<0.05)。结论:CIK细胞可以提高子宫内膜癌患者机体免疫功能,改善患者一般状态。

Clinical observation on the changes of T lymphocytes subgroups and NK cells in peripheral blood of patients with endometrial cancer treated with CIK cells

Objective:To observe the clinical efficacy of cytokine-induced killer(CIK) cells combined with chemotherapy,endocrine therapy for endometrial cancer.Methods:Thirty-five patients with endometrial cancer were treated with biotherapy of CIK cells for 6 courses of treatment,including 11 patients treated with chemotherapy(taxol and platinol) combined with biotherapy of CIK cells,15 patients treated with endocrine therapy of megestrol acetate combined with biotherapy of CIK cells,and 9 patients treated with simple biotherapy of CIK cells.The changes of CD3+ lymphocytes subgroup,CD4+ lymphocytes subgroup,the ratio of CD4+/CD8+,proportion of NK cells,and KPS scores before and after treatment were detected by flow cytometry,then the results were analyzed retrospectively.Results:After treatment,CD3+ cells of 35 patients with endometrial cancer didn't change significantly,CD4+ helper T lymphocytes increased significantly,the ratio of CD4+/CD8+ increased significantly,CD3-/CD16+56+ cells of some patients increased after treatment,but there was no statistically significant difference between before and after treatment,the mean KPS score after treatment increased by 10(P<0.05).Conclusion:CIK cells can improve the immune function and general status of patients with endometrial cancer.